Pembrolizumab monotherapy showed durable antitumour activity and manageable safety in patients with metastatic triple-negative breast cancer. We aimed to examine whether the addition of pembrolizumab would enhance the antitumour activity of chemotherapy in patients with metastatic triple-negative breast cancer...
Biosimilars Brain Cancer Breast CancerBreast Cancer CAR T-cell Therapy COVID-19 Disparities in Cancer Care Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer Genitourinary CancersGenitourinary CancersGenitourinary Cancers ...
Common side effects of KEYTRUDA when given with certain chemotherapy medicines include feeling tired or weak; nausea; constipation; diarrhea; decreased appetite; rash; vomiting; cough; trouble breathing; fever; hair loss; inflammation of the nerves that may cause pain, weakness, and paralysis in the...
Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina Apr 17th 2025 - May 23rd 2025 online-activity View More Video Addressing Unmet Needs in HER2+ Metastatic BTC Apr 24th 20...
Pembrolizumabis a programmed death receptor-1 (PD-1)blocking antibodythat was evaluated in a multicenter phase 1bclinical trial(KEYNOTE-012) for patients with PD-L1 positive recurrent or metastaticsquamous cellcarcinoma of the head and neck[6, 7, 37]. Out of the 104 patients who were screene...
In KEYNOTE-355, when KEYTRUDA (pembrolizumab) and chemotherapy (paclitaxel, paclitaxel protein-bound, or gemcitabine and carboplatin) were administered to patients with locally recurrent unresectable or metastatic TNBC who had...
Immunochemotherapy with pembrolizumab has been integrated into clinical practice as part of the standard-of-care for non-metastatic triple-negative breast cancer (TNBC) with high risk. We conducted a real-world study in TNBC patients treated with neoadjuvant chemotherapy to compare pathologic complete ...
Briefly, eligible patients were 18 years or older with centrally confirmed, newly diagnosed, previously untreated, nonmetastatic TNBC (tumor stage T1c, nodal stage N1-2 or tumor stage T2-4, nodal stage N0-2 per the American Joint Committee on Cancer20) as determined by investigator ...
In KEYNOTE-355, when KEYTRUDA and chemotherapy (paclitaxel, paclitaxel protein-bound, or gemcitabine and carboplatin) were administered to patients with locally recurrent unresectable or metastatic TNBC who had not been previously ...
2. Cortés J, Cescon DW, Rugo HS, et al: KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab plus chemotherapy vs placebo plus chemotherapy for metastatic TNBC.Ann Oncol 32:S1289-S1290, 2021. ...